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Background
PSA-TRICOM is a vector-based therapeutic cancer vaccine
designed to generate a targeted anti-tumor immune
response against prostate-specific antigen (PSA)-expressing
tumor cells. Early clinical trials have evaluated the impact
of this vaccine on the immune system and demonstrated
promising clinical activity. Although many patients with
prostate cancer are advanced in age, little is known about
how these shifts in immune phenotype affect responses to
immunotherapies such as cancer vaccines.
Methods
We conducted a broad overview of both published and new
data to analyze the immune responses to PSA-TRICOM.
Immune responses included ELISPOT for antigen-specific
immune response and flow-cytometry analysis of peripheral
immune cells.
Results
104 patients with prostate cancer were tested for PSA-
specific T lymphocyte responses to PSA-TRICOM. Age
of patients ranged from 47-87 years, with a median of
66.3 years. Spearman correlation coefficient was used to
interrogate an association between the age of patients
and magnitude of antigen-specific T lymphocyte
response. There was no association between age and
immune response as measured by the ratio of maximum
PSA spots/million to PSA spots/million prior to vaccine
(r = 0.099; p = 0.32). Influenza responses were assessed
by ELISPOT as standard controls, with no differences
observed based on age. For most patients PSA-specific
immune responses (likely memory cells) seen 28 days fol-
lowing the most recent vaccine are quantitatively similar
to levels of circulating influenza-specific T cells in the
same patients.
Conclusion
There is minimal understanding about how responses to
immune-based therapies vary with age. We found no evi-
dence that the magnitude of immune responses generated
by PSA-TRICOM is correlated with age of treated
patients. This suggests that elderly patients may derive
equal benefit from immune-based therapies as their
younger counterparts. Further immune analysis continues
in an ongoing Phase III of PSA-TRICOM in metastatic
castration resistant prostate cancer (NCT01322490), cur-
rently accruing worldwide, and 2 trials combining PSA-
TRICOM with Enzalutamide (biochemical recurrence/
NCT01875250 and mCRPC/NCT01867333), which are
currently accruing at the NCI.
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